➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Merck
Harvard Business School
AstraZeneca
Express Scripts

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,387,180

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,387,180
Title:
Abstract:
Inventor(s):
Assignee:
Application Number:
Patent Claims:1. A polymeric nanoparticle encapsulating a plurality of nanocarriers, wherein: said plurality of nanocarriers are in a form selected from the group consisting of nanocapsules and nanospheres; at least a portion of the plurality of nanocarriers comprises at least one active agent; and said nanoparticle is prepared by nanospraying and has an average diameter of between 400 and 950 nm.

2. The nanoparticle of claim 1, wherein the plurality of nanocarriers are obtainable by nanospraying.

3. The nanoparticle of claim 1, wherein a material of the nanoparticle and/or a material of the plurality of nanocarriers are cross-linked.

4. The nanoparticle of claim 1, wherein the plurality of nanocarriers further comprises a polycationic lipid being 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP).

5. The nanoparticle of claim 1, being in a form of a nanocapsule or a nanosphere independent of the form of the plurality of nanocarriers.

6. The nanoparticle of claim 1, wherein said active agent is selected from the group consisting of a vitamin, a protein, an anti-oxidant, a nucleic acid, a short or long oligonucleotide, a siRNA, chemical derivatives of siRNA, a peptide, a polypeptide, a lipid, a carbohydrate, a hormone, an antibody, a monoclonal antibody, a vaccine, a prophylactic agent, a drug, a diagnostic agent, a contrasting agent, a nutraceutical agent, a small molecule, an electrolyte, an immunological agent, and combinations thereof.

7. The nanoparticle of claim 6, wherein the active agent is siRNA.

8. The nanoparticle of claim 6, wherein said active agent is hydrophobic and is selected from the group consisting of an analgesic agent; an anti-inflammatory agent; an enthelmintic agent; an anti-arrhythmic agent; an anti-bacterial agent; an anti-coagulant; an anti-depressant; an antidiabetic; an anti-epileptic; an anti-fungal agent; an anti-gout agent; an anti-hypertensive agent; an anti-malarial agent; an anti-migraine agent; an anti-muscarinic agent; an anti-neuroplastic agent; an immunosuppressant; an anti-protazoal agent; an anti-thyroid agent; an alixiolytic; a sedative; a hypnotic; a neuroleptic agent; a beta-blocker; a cardiac inotropic agent; a corticosteroid; a diuretic agent; an anti-Parkinsonian agent; a gastro-intestinal agent; an histamine H1-receptor antagonist; a lipid regulating agent; a nitrate; an anti-anginal agent; a nutritional agent; an HIV protease inhibitor; an opioid analgesic; a sex hormone; and a stimulant agent.

9. The nanoparticle of claim 1, having an outer surface associated with at least one targeting agent.

10. The nanoparticle of claim 9, wherein said at least one targeting agent is selected from the group consisting of a monoclonal antibody; a small molecule; hyaluronic acid; hyaluronan; tumor penetrating peptides; epidermal growth factor (EGF); transferrin; ferritin; Arginine-Glycine-Aspartic acid (RGD) peptide; epithelial cell adhesion molecule (EpCAM); intercellular adhesion molecule 1 (ICAM-1); carcinoembrionic antigen (CEA); vasoactive intestinal peptide; CA 15-3 antigen; MUC1 protein; CD20; CD33; integrins; lymphatic targeting moieties; aptamers; and oligosaccharides.

11. The nanoparticle of claim 10, wherein said monoclonal antibody is selected from the group consisting of trastuzumab; AMBLK8; cetuximab; Rituximab; ranibizumab; and bevacizumab.

12. The nanoparticle of claim 11, wherein said at least one targeting agent is selected from ranibizumab and bevacizumab.

13. The nanoparticle of claim 10, wherein said small molecule is selected from the group consisting of folic acid and folate.

14. The nanoparticle according to claim 1, wherein said active agent is contained within the at least a portion of the plurality of nanocarriers or associated with a region of an outer surface of the at least a portion of the plurality of nanocarriers.

15. The nanoparticle of claim 9, wherein said at least a portion of the plurality of nanocarriers has an outer surface associated with at least one further targeting agent.

16. The nanoparticle of claim 15, wherein said at least one targeting agent is identical to said at least one further targeting agent.

17. The nanoparticle of claim 15, wherein said at least one targeting agent is different from said at least one further targeting agent.

18. The nanoparticle of claim 1, wherein said at least one active agent is negatively or positively charged.

19. The nanoparticle of claim 18, wherein said active agent is negatively charged and the at least a portion of the plurality of nanocarriers further comprises a cationic lipid or a cell penetrating peptide.

20. The nanoparticle of claim 19, wherein said cationic lipid is selected from the group consisting of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), stearylamine, and oleylamine.

21. The nanoparticle of claim 19, wherein said cell penetrating peptide is selected from the group consisting of HIV-TAT, penetratin, Gramicidin S, MSI-103, MSI-103-Arg, PGLa, PGLa-Arg, Magainin 2, Magainin-2-Arg, KIGAKI, BP100, MAP, MAP-Arg, SAP, PEP-1, transportan, and FP23.

22. A process for obtaining the nanoparticle of claim 1, the process comprising: (a) obtaining at least one nanocarrier, said nanocarrier comprising at least one active agent; and (b) encapsulating said at least one nanocarrier into said nanoparticle.

23. A nanospraying process for obtaining the nanoparticle of claim 1, the process comprising: transporting through a screen having one or more orifices of a predetermined size a colloidal composition comprising a plurality of nanocarriers and a nanoparticle material in a liquid medium, wherein: said plurality of nanocarriers comprises at least one active agent, said nanoparticle material is at least partially soluble in said liquid medium, and the size of said orifices determines a size of the nanoparticles.

24. The nanoparticle of claim 1, wherein: a material of the plurality of nanocarriers and the active agent are both hydrophilic or a material of the plurality of nanocarriers and the active agent are both hydrophobic; and a material of the nanoparticle is hydrophilic or hydrophobic.

25. The nanoparticle of claim 24, wherein a hydrophobic material of the nanoparticle and/or the plurality of nanocarriers is selected from the group consisting of lactic acid, poly(D,L-lactic-co-glycolic acid) (PLGA), poly(D,L-lactic acid) (PLA), poly(c-caprolactone), poly(2-dimethylamino-ethylmethacrylate) homopolymer, poly(2-dimethylamino-ethylmethacrylate)-b-poly(ethyleneglycol)-.alpha.-me- thoxy-.omega.-methacrylate copolymers, polycyanoacrylates, polyanhydride polymers, and combinations thereof.

26. The nanoparticle of claim 24, wherein: said material of the nanoparticle is hydrophobic, and an outer surface of said nanoparticle is associated with at least one polyethylene glycol (PEG) moiety.

27. The nanoparticle of claim 24, wherein a hydrophilic material of the nanoparticle and/or the plurality of nanocarriers is selected from the group consisting of dextran, hylauronate, normal or cross-linked human serum albumin (HSA), normal or cross-linked bovine serum albumin (BSA), chitosan, shellac, collagen, gelatin, gum arabic, polyvinyl alcohol, cyclodextrin, and combinations thereof.

28. The nanoparticle of claim 27, wherein said active agent is hydrophilic and is selected from the group consisting of therapeutic peptides and proteins.

29. The nanoparticle of claim 27, wherein said active agent is hydrophilic and is selected from the group consisting of exenatide, insulin, growth hormone, triptorelin acetate, buserelin, and nafarelin.

Summary for Patent:   Start Trial

PCT Information
PCT FiledSeptember 20, 2012PCT Application Number:PCT/IL2012/050382
PCT Publication Date:March 28, 2013PCT Publication Number:WO2013/042125

Details for Patent 9,387,180

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial 2039-03-29 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial 2039-03-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Boehringer Ingelheim
Merck
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.